Linked Life Data

16417598

Source:http://linkedlifedata.com/resource/pubmed/id/16417598

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2006-1-18
pubmed:abstractText
Most of the initial reports on botulinum toxin in tension-type headache (TTH) and in migraine were positive. Unfortunately, these results were not reproduced in well-designed, randomized controlled trials. So far, doses from 20 U (Botox) to 500 U (Dysport) have been studied in patients with chronic TTH, and doses from 16 to 200 U (Botox) in patients with migraine. Overall, there is no evidence for a beneficial effect of botulinum toxin, although trends favoring botulinum toxin were reported. Experience with botulinum toxin type B (Myobloc/NeuroBloc) is limited and similar to the experience with the type A. Thus, a widespread use of botulinum toxin therapy in headache can currently not be recommended.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1351-5101
pubmed:author
pubmed:issnType
Print
pubmed:volume
13 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
51-4
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Botulinum toxin therapy of migraine and tension-type headache: comparing different botulinum toxin preparations.
pubmed:affiliation
Department of Neurology, University of Regensburg, Regensburg, Germany. wilhelm.schulte-mattler@klinik.uni-regensburg.de
pubmed:publicationType
Journal Article, Review